Clinical Trials · NCT02049866

Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

CompletedPhase 2Teriparatide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Elizabeth Shane
Enrollment
33
Start date
Nov 2014
Locations
2 sites, United States
Primary endpoint
Percent Change in Lumbar Spine Areal BMD by DXA
View Teriparatide compound reference